What is the current market size and future outlook for the cell free dna (cfdna) testing market?
The cell free dna (cfDNA) testing market size has grown exponentially in recent years. It will grow from $8.74 billion in 2024 to $10.86 billion in 2025 at a compound annual growth rate (CAGR) of 24.2%. The growth in the historic period can be attributed to a rise in the adoption of cfDNA testing in prenatal care, increasing use of cfDNA analysis, growing interest in cfDNA research across various medical fields, and rise in gaining approvals from regulatory bodies.
The cell free dna (cfDNA) testing market size is expected to see exponential growth in the next few years. It will grow to $25.56 billion in 2029 at a compound annual growth rate (CAGR) of 23.9%. The growth in the forecast period can be attributed to a shift towards personalized medicine, enhancements in healthcare infrastructure, aging population and increasing incidence of cancer, increasing adoption of precision medicine, increasing awareness and acceptance of liquid biopsy techniques, and increasing investment and funding in cfDNA research. Major trends in the forecast period include adoption of liquid biopsy technologies, advancements in Next-Generation Sequencing (NGS) technology, integration of AI and machine learning in cfDNA testing, development of point-of-care cfDNA tests, and implementation of cloud-based platforms for data storage and analysis.
Get Your Free Sample of The Global Cell Free DNA (cfDNA) Testing Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15757&type=smp
How has the cell free dna (cfdna) testing market evolved, and what factors have shaped its growth?
The rising prevalence of cancer is expected to propel the growth of the cell-free DNA (cfDNA) testing market going forward. Cancer is a complex group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. These cells can invade and destroy normal tissue and, if not controlled, can significantly harm the body. The prevalence of cancer is due to aging populations, shifts in lifestyle, environmental influences, and advancements in detection and diagnostic techniques. cfDNA testing detects genetic mutations associated with cancer at an early stage, often before symptoms appear. This allows for early intervention, improving patient outcomes and survival rates by identifying cancer in its initial stages. For instance, in February 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, there are expected to be over 35 million new cases of cancer in 2050, a 77% increase over the projected 20 million cases in 2022. Therefore, the rising prevalence of cancer is driving the growth of the cell-free DNA (cfDNA) testing market.
What are the major segments of the cell free dna (cfdna) testing market?
The cell free dna (cfDNA) testing market covered in this report is segmented –
1) By Product: Donor-Derived Cell-Free DNA, Circulating Cell-Free Tumor DNA, Cell-Free Fetal DNA
2) By Platforms: Next Generation Sequencing (NGS), rPCR And Multiplexed PCR, qPCR And dPCR, Other platforms
3) By Application: Oncology, Non-Invasive Prenatal Test (NIPT), Gynecology, Transplantation, Other Applications
Subsegments:
1) By Donor-Derived Cell-Free DNA: Organ Transplant Monitoring, Graft Rejection Detection
2) By Circulating Cell-Free Tumor DNA: Cancer Detection, Minimal Residual Disease Monitoring, Liquid Biopsy
3) By Cell-Free Fetal DNA: Non-Invasive Prenatal Testing (NIPT), Fetal Genetic Disorder Screening
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/cell-free-dna-cfdna-testing-global-market-report
Which companies dominate the cell free dna (cfdna) testing market?
Major companies operating in the cell free DNA (cfDNA) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, Bio-Techne Corporation, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Invitae Corporation, Foundation Medicine Inc., Guardant Health Inc., Integrated DNA Technologies Inc., Caris Life Sciences Inc., Twist Bioscience Corporation, Adaptive Biotechnologies Corporation, Biodesix Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems Inc., Circulogene Theranostics LLC
How will evolving trends contribute to the growth of the cell free dna (cfdna) testing market?
Major companies operating in the cell-free DNA (cfDNA) testing market focus on developing innovative technologies, such as liquid biopsy tests that offer greater sensitivity, specificity, and efficiency in detecting cancer-related mutations and genetic alterations. Liquid biopsy tests refer to diagnostic procedures that allow oncologists to evaluate circulating cell-free DNA released by tumor cells, facilitating personalized, targeted therapy plans. For instance, in May 2023, Laboratory Corporation of America Holdings (Labcorp), a US-based life sciences company, launched Labcorp Plasma Focus, a new liquid biopsy test designed for patients with advanced or metastatic solid tumors. This test evaluates circulating cell-free DNA (cfDNA) released by tumor cells from a standard blood draw, making it minimally invasive and providing fast results. It enhances access to precision oncology by identifying clinically actionable biomarkers across several common cancers, such as non-small cell lung, colorectal, breast, esophageal, gastroesophageal junction, gastric cancers, and melanoma.
What are the key regional dynamics of the cell free dna (cfdna) testing market, and which region leads in market share?
North America was the largest region in the cell-free DNA (cfDNA) testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell free DNA (cfDNA) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Cell Free DNA (cfDNA) Testing Market Report 2025 Offer?
The cell free dna (cfdna) testing market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Cell-free DNA (cfDNA) testing is a non-invasive diagnostic method that analyzes DNA fragments circulating freely in the bloodstream. cfDNA testing is utilized in liquid biopsy procedures and allows for detecting and analyzing genetic mutations and alterations without the need for a traditional tissue biopsy.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15757
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
